Ligand Pharmaceuticals vs Scholar Rock Holding

Ligand Pharmaceuticals (LGND), health care, and Scholar Rock Holding (SRRK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ligand Pharmaceuticals is worth $5.9B on the stock market and Scholar Rock Holding $5.5B: Ligand Pharmaceuticals is valued at 7% more. Over the past year Ligand Pharmaceuticals's share price has moved +45.7% and Scholar Rock Holding's +11.9%.

Key facts

Ligand Pharmaceuticals market value
$5.9B
Scholar Rock Holding market value
$5.5B
Ligand Pharmaceuticals P/E
118
Ligand Pharmaceuticals revenue
$268.1MFY to 2025-12-31
Scholar Rock Holding revenue
$0FY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Ligand Pharmaceuticals vs Scholar Rock Holding: every measure side by side
Measure Ligand Pharmaceuticals Scholar Rock Holding
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$5.9Bhigher$5.5Blower
Revenue$268.1Mhigher$0lower
Earnings$124.5Mhigher-$377.9Mlower
Employees47lower289higher
Total assets$1.6Bhigher$404.3Mlower
Valuation
P/E118—
P/S21.9—
P/B6.1lower32.6higher
Dividend yield0.00%0.00%
Profitability
Operating margin15.3%—
Balance sheet
Net assets$1Bhigher$245.5Mlower
Total liabilities$543.4Mhigher$158.8Mlower
Total debt—$99.7M
Cash on hand$174.9Mlower$323.5Mhigher
Price change
Today-2.62%lower+1.21%higher
1 year+45.7%higher+11.9%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Ligand Pharmaceuticals only (0)

None of the tracked investors.

Scholar Rock Holding only (3)

Percentages are each holding's share of that investor's reported portfolio. · Who owns SRRK

Further comparisons

Learn

Questions and answers

Which is bigger, Ligand Pharmaceuticals or Scholar Rock Holding?

By market value, Ligand Pharmaceuticals is the larger: $5.9B against $5.5B for Scholar Rock Holding. By revenue in its latest fiscal year, Ligand Pharmaceuticals is the larger: $268.1M against $0 for Scholar Rock Holding.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Ligand Pharmaceuticals and Scholar Rock Holding?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Ligand Pharmaceuticals and 3 hold Scholar Rock Holding.

Cite this page

Funkfolio, “Ligand Pharmaceuticals vs Scholar Rock Holding”, data as of 18 November 2026. https://funkfolio.com/compare/lgnd-vs-srrk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.